Loading...
•
Dec 31, 2025
Zevra Q4 2025 Earnings Report
Zevra Q4 2025 Earnings Report
Key Takeaways
Zevra Therapeutics achieved significant revenue growth in Q4 2025, driven by the strong commercial launch of MIPLYFFA for Niemann-Pick disease type C. The company transitioned to profitability for the quarter and full year, bolstered by the sale of a Priority Review Voucher and disciplined expense management.
Q4 net revenue grew 31% quarter-over-quarter to $34.1 million.
MIPLYFFA generated $26.4 million in Q4 net revenue, representing the primary growth driver.
The company reported a net income of $12.2 million for Q4 2025, compared to a net loss in the prior year period.
Cash and securities reached $238.9 million, providing sufficient resources to execute strategic priorities independent of capital markets.
Revenue by Segment
Forward Guidance
Zevra is focused on executing multiple near-term growth opportunities in 2026, including potential European expansion and accelerating the celiprolol development program.
Positive Outlook
- Anticipated response to EMA 120-day questions for arimoclomol review.
- Engagement with FDA to accelerate the celiprolol development program.
- Sufficient financial flexibility to execute strategic priorities without capital markets.
- Relocation to Boston to access specialized talent pool.
- Continued expansion of MIPLYFFA market access and global EAP.
Challenges Ahead
- Increased SG&A expenses due to commercial launch activities.
- Potential for regulatory delays in European approval process.
- Risk of embryofetal toxicity and hypersensitivity reactions impacting product usage.
- Dependence on successful execution of the DiSCOVER trial events.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...